Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Invasive Breast Carcinoma: early-phase trial registry
16 of 46 indexed Invasive Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #312 of 28,707 conditions by registered trial count.
46 US clinical trials · 16 currently recruiting · #312 of 28,707 conditions by registered trial count
Invasive Breast Carcinoma: 46 US clinical trials tracked, 16 recruiting.
Invasive Breast Carcinoma is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 14 of these trials.
Enrollment posture brief
Registry condition invasive-breast-carcinoma
OPEN 16 | RECR 35% | LATE 7 | EARLY 26 | RANK #312 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Metastatic Melanoma (35% recruiting · 92 trials)
Invasive Breast Carcinoma lists 16 open slots (35% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Invasive Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Invasive Breast Carcinoma is recruiting below its size-band peers.
16 of 46 indexed trials (34.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Invasive Breast Carcinoma research.
M.D. Anderson Cancer Center accounts for 14 of 46 trials (30.4%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Invasive Breast Carcinoma enrolment sits around 120 participants.
Median target enrolment is 120 among the 46 trials that report a genuine target (sentinel values excluded). 19 of those (41.3%) plan for fewer than 100 participants.
-
Invasive Breast Carcinoma research is mostly interventional.
40 interventional and 6 observational studies make up this index (87% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
46 total, page 1 of 1
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Guardant Health
NCT05059444
Breast Cancer Survivorship Biorepository
University of Southern California
NCT05786664
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT00477100
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
M.D. Anderson Cancer Center
NCT04169542
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
City of Hope Medical Center
NCT06763328
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
NCT03971409
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
M.D. Anderson Cancer Center
NCT02945579
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Thomas Jefferson University
NCT04959474
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
NCT03606967
Neoadjuvant Breast Cancer Time Restricted Eating
Thomas Jefferson University
NCT05327608
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Mayo Clinic
NCT04521764
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Emory University
NCT05464810
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
NCT07137416
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
NCT05319873
NearWave Optical Molecular Monitoring
Indiana University
NCT06744465
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
M.D. Anderson Cancer Center
NCT05406232
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
NCT01272037
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ECOG-ACRIN Cancer Research Group
NCT04266249
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02954874
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
NCT04457596
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
Alliance for Clinical Trials in Oncology
NCT03414970
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT02912312
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center
NCT02276443
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ECOG-ACRIN Cancer Research Group
NCT02445391
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01266642
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
ECOG-ACRIN Cancer Research Group
NCT05710328
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
City of Hope Medical Center
NCT05340673
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
M.D. Anderson Cancer Center
NCT01245712
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
Northwestern University
NCT04009044
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Virginia Commonwealth University
NCT02515110
Metformin and Nightly Fasting in Women With Early Breast Cancer
M.D. Anderson Cancer Center
NCT05023967
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center
NCT00877500
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
Northwestern University
NCT05545150
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
Rutgers, The State University of New Jersey
NCT04871516
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
NCT01750073
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02883062
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02453620
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
NCT02957968
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
NCT04647916
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
NCT02876107
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
Mayo Clinic
NCT04897009
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
NCT03359954
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
Rutgers, The State University of New Jersey
NCT02526498
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
NCT02530489
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
M.D. Anderson Cancer Center
NCT02282345
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 20 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Invasive Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Invasive Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Invasive Breast Carcinoma page
46 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Invasive Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Invasive Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Invasive Breast Carcinoma condition card totals 46 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.